Golimumab in the treatment of psoriatic arthritis: efficacy and safety
Tumor necrosis factor-α (TNF-α) holds a central position in the pathogenesis of autoimmune inflammatory diseases of the locomotor apparatus. A separate class of drugs, namely, TNF-α inhibitors, that are effective against multicomponent diseases, such as psoriatic arthritis (PsA), is now available to...
Main Authors: | Tatiana Viktorovna Korotaeva, E. Yu. Loginova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2015-09-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/639 |
Similar Items
-
Tumor necrosis factor-? inhibitors in therapy for psoriatic arthritis
by: Vladimir Vasilyevich Badokin, et al.
Published: (2010-12-01) -
Long-term results of golimumab therapy for rheumatoid arthritis. Therapy compliance issues
by: N. V. Chichasova
Published: (2016-06-01) -
Efficacy of golimumab in treating uveitis in patients with ankylosing spondylitis
by: T. V. Dubinina, et al.
Published: (2016-09-01) -
Golimumab in the treatment of inflammatory diseases: A role of immunogenicity
by: D. E. Karateev
Published: (2016-01-01) -
Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis
by: A. B. Demina
Published: (2019-10-01)